TABLE 4.
Neutralization of an AAV vector by sera from B6 mice exposed to an AAV vector with or without CTLA4Ig and/or MR1 immunosuppressiona
Primary vector | Treatment | No. of animals | Vector neutralization (%) for serum dilution indicatedb:
|
|
---|---|---|---|---|
1:20 | 1:100 | |||
None (saline) | None | 3 | 0, 0, 0 | 0, 0, 0 |
AAV-βgal | L6 + HIg | 4 | 100, 100, 100, 100 | 100, 100, 100, 100 |
AAV-βgal | MR1 + CTLA4Ig | 4 | 0, 0, 0, 0 | 0, 0, 0, 0 |
AAV-βgal | CTLA4Ig | 4 | 100, 100, 4.7, 100 | 100, 50, 0, 100 |
AAV-βgal | MR1 | 5 | 100, 100, 100, 100, 100 | 89, 38, 100, 100, 10 |
B6 mice were given saline or AAV-βgal (as described in Table 3) in the presence or absence of immunomodulating drugs. Fifty-four days later, serum samples were obtained and analyzed for neutralizing activity to AAV vector.
Neutralization values for serum samples from individual animals are given in the same order for each serum dilution.